Ofatumumab in refractory anti-muscle-specific tyrosine kinase antibody-positive myasthenia gravis: a case report of successful salvage therapy and mechanistic insights
Muscle-specific tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG), a subtype of myasthenia gravis (MG), follows an acute and severe disease course with suboptimal responses to standard treatments. Ofatumumab is a fully humanized anti-CD20 monoclonal antibody that induces potent and susta...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2026-06-01
|
| Edice: | Frontiers in Immunology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1792262/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|